162 related articles for article (PubMed ID: 10482983)
1. Selective usage of D-type cyclins in lymphoid malignancies.
Suzuki R; Kuroda H; Komatsu H; Hosokawa Y; Kagami Y; Ogura M; Nakamura S; Kodera Y; Morishima Y; Ueda R; Seto M
Leukemia; 1999 Sep; 13(9):1335-42. PubMed ID: 10482983
[TBL] [Abstract][Full Text] [Related]
2. Detection of cyclin D1 (bcl-1, PRAD1) overexpression by a simple competitive reverse transcription-polymerase chain reaction assay in t(11;14)(q13;q32)-bearing B-cell malignancies and/or mantle cell lymphoma.
Uchimaru K; Taniguchi T; Yoshikawa M; Asano S; Arnold A; Fujita T; Motokura T
Blood; 1997 Feb; 89(3):965-74. PubMed ID: 9028328
[TBL] [Abstract][Full Text] [Related]
3. Expression of D-type cyclins in normal and neoplastic rat pituitary.
Qian X; Kulig E; Jin L; Lloyd RV
Endocrinology; 1998 Apr; 139(4):2058-67. PubMed ID: 9528994
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of cyclin D2 in chronic B-cell malignancies.
Delmer A; Ajchenbaum-Cymbalista F; Tang R; Ramond S; Faussat AM; Marie JP; Zittoun R
Blood; 1995 May; 85(10):2870-6. PubMed ID: 7742549
[TBL] [Abstract][Full Text] [Related]
5. Cyclins D1 and D2 are differentially expressed in human B-lymphoid cell lines.
Palmero I; Holder A; Sinclair AJ; Dickson C; Peters G
Oncogene; 1993 Apr; 8(4):1049-54. PubMed ID: 8455931
[TBL] [Abstract][Full Text] [Related]
6. Expression of cyclin D2 and D3 in lymphoid lesions.
Teramoto N; Pokrovskaja K; Szekely L; Polack A; Yoshino T; Akagi T; Klein G
Int J Cancer; 1999 May; 81(4):543-50. PubMed ID: 10225442
[TBL] [Abstract][Full Text] [Related]
7. Characterization of D-cyclin proteins in hematolymphoid neoplasms: lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes.
Metcalf RA; Zhao S; Anderson MW; Lu ZS; Galperin I; Marinelli RJ; Cherry AM; Lossos IS; Natkunam Y
Mod Pathol; 2010 Mar; 23(3):420-33. PubMed ID: 20062012
[TBL] [Abstract][Full Text] [Related]
8. Selective usage of D-Type cyclins by Ewing's tumors and rhabdomyosarcomas.
Zhang J; Hu S; Schofield DE; Sorensen PH; Triche TJ
Cancer Res; 2004 Sep; 64(17):6026-34. PubMed ID: 15342383
[TBL] [Abstract][Full Text] [Related]
9. Independent regulation of human D-type cyclin gene expression during G1 phase in primary human T lymphocytes.
Ajchenbaum F; Ando K; DeCaprio JA; Griffin JD
J Biol Chem; 1993 Feb; 268(6):4113-9. PubMed ID: 8382693
[TBL] [Abstract][Full Text] [Related]
10. Distinct proliferative and transcriptional effects of the D-type cyclins in vivo.
Mullany LK; White P; Hanse EA; Nelsen CJ; Goggin MM; Mullany JE; Anttila CK; Greenbaum LE; Kaestner KH; Albrecht JH
Cell Cycle; 2008 Jul; 7(14):2215-24. PubMed ID: 18635970
[TBL] [Abstract][Full Text] [Related]
11. Cyclin D1 expression in mantle cell lymphoma is accompanied by downregulation of cyclin D3 and is not related to the proliferative activity.
Ott MM; Bartkova J; Bartek J; Dürr A; Fischer L; Ott G; Müller-Hermelink HK; Kreipe H
Blood; 1997 Oct; 90(8):3154-9. PubMed ID: 9376597
[TBL] [Abstract][Full Text] [Related]
12. The expression and activity of D-type cyclins in F9 embryonal carcinoma cells: modulation of growth by RXR-selective retinoids.
Li Y; Glozak MA; Smith SM; Rogers MB
Exp Cell Res; 1999 Dec; 253(2):372-84. PubMed ID: 10585260
[TBL] [Abstract][Full Text] [Related]
13. Expression of cyclins D1, D2, and D3 and Ki-67 in Leukemia.
Jaroslav P; Martina H; Jirí S; Hana K; Petr S; Tomás K; Julius M; Cedrik H
Leuk Lymphoma; 2005 Nov; 46(11):1605-1612. PubMed ID: 16334487
[TBL] [Abstract][Full Text] [Related]
14. D-type cyclins in adult human testis and testicular cancer: relation to cell type, proliferation, differentiation, and malignancy.
Bartkova J; Rajpert-de Meyts E; Skakkebaek NE; Bartek J
J Pathol; 1999 Apr; 187(5):573-81. PubMed ID: 10398124
[TBL] [Abstract][Full Text] [Related]
15. Retinoid targeting of different D-type cyclins through distinct chemopreventive mechanisms.
Ma Y; Feng Q; Sekula D; Diehl JA; Freemantle SJ; Dmitrovsky E
Cancer Res; 2005 Jul; 65(14):6476-83. PubMed ID: 16024653
[TBL] [Abstract][Full Text] [Related]
16. Elimination of cyclin D1 in vertebrate cells leads to an altered cell cycle phenotype, which is rescued by overexpression of murine cyclins D1, D2, or D3 but not by a mutant cyclin D1.
Lahti JM; Li H; Kidd VJ
J Biol Chem; 1997 Apr; 272(16):10859-69. PubMed ID: 9099742
[TBL] [Abstract][Full Text] [Related]
17. Protein Expression for Novel Prognostic Markers (Cyclins D1, D2, D3, B1, B2, ITGβ7, FGFR3, PAX5) Correlate With Previously Reported Gene Expression Profile Patterns in Plasma Cell Myeloma.
Mansoor A; Akhter A; Pournazari P; Mahe E; Shariff S; Farooq F; Elyamany G; Shahbani-Rad MT; Rashid-Kolvear F
Appl Immunohistochem Mol Morphol; 2015; 23(5):327-33. PubMed ID: 25265432
[TBL] [Abstract][Full Text] [Related]
18. Phenotype-related differences in the expression of D-type cyclins in human B cell-derived lines.
Pokrovskaja K; Ehlin-Henriksson B; Bartkova J; Bartek J; Scuderi R; Szekely L; Wiman KG; Klein G
Cell Growth Differ; 1996 Dec; 7(12):1723-32. PubMed ID: 8959341
[TBL] [Abstract][Full Text] [Related]
19. Requirement for cyclin D3 in lymphocyte development and T cell leukemias.
Sicinska E; Aifantis I; Le Cam L; Swat W; Borowski C; Yu Q; Ferrando AA; Levin SD; Geng Y; von Boehmer H; Sicinski P
Cancer Cell; 2003 Dec; 4(6):451-61. PubMed ID: 14706337
[TBL] [Abstract][Full Text] [Related]
20. Activation of cyclin D1 and D2 promoters by human T-cell leukemia virus type I tax protein is associated with IL-2-independent growth of T cells.
Mori N; Fujii M; Hinz M; Nakayama K; Yamada Y; Ikeda S; Yamasaki Y; Kashanchi F; Tanaka Y; Tomonaga M; Yamamoto N
Int J Cancer; 2002 May; 99(3):378-85. PubMed ID: 11992406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
